Key facts
- It has raised $2.0M; the latest was Seed Round ($2.0M) in Jul 2025.
- Notable investors include M2M (Consulting Services (B2B)), UniQuest Extension Fund, Uniseed.
- Status: Privately Held (backing).
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for Lucia Bio
- ·The full record, as it builds
Funding rounds
No funding rounds for Lucia Bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Lucia Bio
Developer of small molecule inhibitors intended for therapeutic application in immune-related diseases. The company offers compounds with tailored drug-like properties that target a clinically validated kinase, supported by preclinical data across neuroinflammatory, autoimmune, and hematologic indications, enabling pharmaceutical researchers and clinical developers to pursue precision treatment strategies with enhanced selectivity, reduced off-target effects, and potential for broad disease coverage.
- Sector
- Healthcare
- HQ
- Camberwell, Australia
- Founded
- 2024
- Employees
- 4
- Website
- lucia.bio/
- Ownership
- Privately Held (backing)
Lucia Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Lucia Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Lucia Bio in its N-PORT filings yet. We sweep new filings monthly.